Results 181 to 190 of about 57,090 (240)

A Case of Cytokine Release Syndrome Induced by Avelumab and Axitinib Combination Therapy for Metastatic Renal Cell Carcinoma

open access: yesIJU Case Reports, Volume 9, Issue 2, March 2026.
ABSTRACT Introduction Cytokine release syndrome (CRS) is a rare immune‐related adverse event of immune checkpoint inhibitors (ICIs). At present, its association with avelumab–axitinib therapy for renal cell carcinoma (RCC) has yet to be reported. Differentiating early CRS from an infusion‐related reaction (IRR) is clinically challenging, particularly ...
Rio Shibata   +7 more
wiley   +1 more source

Durable Disease Control With Nivolumab in Malignant Epithelioid Angiomyolipoma: A Case Report

open access: yesIJU Case Reports, Volume 9, Issue 2, March 2026.
ABSTRACT Introduction Epithelioid angiomyolipoma is a subtype of perivascular epithelioid cell tumors that may exhibit malignant behavior. While mammalian target of rapamycin inhibitors are commonly used for systemic treatment, the efficacy of immune checkpoint inhibitors remains unclear.
Hiroki Shimoda   +9 more
wiley   +1 more source

From Pharmaceutical to Biophysical Therapies: New Horizons in Inflammatory Bowel Disease Management

open access: yesJCC Plus, Volume 1, Issue 2, March 2026.
Important limitations exist in the current pharmacological landscape of Inflammatory Bowel Disease (IBD), such as variable response rates and treatment‐limiting adverse effects. In this review, we perform a critical assessment of the current literature on novel multimodal biophysical approaches showing alternative mechanisms of action to, and potential
Benedetta Ricchi   +7 more
wiley   +1 more source

Fully Automated Plane Prescription in Cardiac MRI: A Prospective Cohort Study

open access: yesJournal of Magnetic Resonance Imaging, Volume 63, Issue 3, Page 891-903, March 2026.
ABSTRACT Background Accurate plane positioning is important for high‐quality cardiac MRI images but requires specialized training, limiting accessibility. Purpose To evaluate an automated plane positioning tool and compare it with manual planning. Study Type Prospective.
Benjamin Böttcher   +10 more
wiley   +1 more source

Development and Characterisation of a Starvation‐ and Exercise‐Induced Murine Model of Microvesicular Steatosis Relevant to Anorexia Nervosa

open access: yesLiver International Communications, Volume 7, Issue 1, March 2026.
ABSTRACT Anorexia nervosa (AN) leads to severe dietary restriction, low body weight, and in many patients, hepatocellular steatosis. Clinically, hepatic fat in AN is usually macrovesicular, whereas microvesicular steatosis is more often associated with severe starvation and mitochondrial dysfunction.
Michiko Ishii   +9 more
wiley   +1 more source

Extracellular Vesicles‐Functionalized Biomaterials for Oral Disease Theragnostics

open access: yesMedComm – Biomaterials and Applications, Volume 5, Issue 1, March 2026.
Combining EVs with biomaterials enables sustained, targeted delivery and overcomes traditional limitations. EVs show great promise in diagnosing and treating oral diseases, and could transform oral health management strategies. ABSTRACT Oral diseases impair oral function and are closely linked to various systemic conditions.
Zhe Zhao, Yiyu Zeng, Rui Liu, Xuemei Qiu
wiley   +1 more source

Spironolactone and Fibrosis in Heart Failure Risk: Machine Learning Analysis of HOMAGE Trial Plasma Proteomics

open access: yesMedComm, Volume 7, Issue 3, March 2026.
In HOMAGE, 276 plasma proteins were profiled using Olink panels. Machine learning algorithms identified galectin‐9 (GAL9), thrombospondin‐2 (THBS2), and NT‐proBNP as predictors of changes in procollagen type I C‐terminal propeptide (PICP) after spironolactone treatment.
Susana Ravassa   +20 more
wiley   +1 more source

Safety and Efficacy of Lucitanib Plus Toripalimab in Advanced Solid Tumors Refractory to Standard Therapies: An Open‐Label, Multicenter, Phase II Study

open access: yesMedComm, Volume 7, Issue 3, March 2026.
Lucitanib plus toripalimab showed manageable safety and encouraging antitumor activity in advanced solid tumors, particularly in PD‐1‐refractory nasopharyngeal carcinoma and recurrent endometrial carcinoma. Clinical responses were observed across subgroups regardless of prior immunotherapy.
Ting Zhou   +24 more
wiley   +1 more source

Home - About - Disclaimer - Privacy